| Literature DB >> 18804997 |
Carine Domenech1, Mariette Mercier, Emmanuel Plouvier, Marc Puraveau, Pierre Bordigoni, Gérard Michel, Yves Benoit, Guy Leverger, André Baruchel, Yves Bertrand.
Abstract
We report on the efficiency of treatment of first isolated extramedullary relapse of B-cell precursor acute lymphoblastic leukaemia. Sixty-eight children and adolescents were included in the trial COPRALL-97. Stratification criteria were time to relapse: first complete remission duration of less than 24 months for group G3A (n=35), relapse beyond 24 months for group G3B (n=33). Treatment consisted of risk-adapted alternating short course multiagent systemic and intrathecal chemotherapy and irradiation (18Gy). Event free survival (EFS) and overall survival (OS) for all registered patients at 6 years were 43% and 55%, respectively. EFS at 4 years for patients of group G3A and G3B were, respectively, 31% and 61% (p=0.0071) while OS at 4 years were, respectively, 40% and 76% (p=0.065). Our analyses highlighted two independent risks factors predictive of decreased EFS: early relapse and age at the initial diagnosis above 6 years. Early central nervous system relapses have a bad prognosis, and new therapeutic strategies are needed.Entities:
Mesh：
Year: 2008 PMID： 18804997 DOI： 10.1016/j.ejca.2008.08.007
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162